文献速递肿瘤 PET/CT

胰腺局灶性68Ga-FAPI-04摄取的非恶性发现

Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-01-15

本研究回顾性分析103例接受68Ga-FAPI-04 PET/MR患者的影像数据,其中7例胰腺出现局灶性摄取增高,4例同期行18F-FDG PET/CT。所有胰腺病灶经病理或随访证实为非肿瘤性,包括胰腺假性囊肿、既往胰腺炎部位和IgG4相关疾病病灶。提示68Ga-FAPI-04局灶性摄取可发生于良性胰腺病变,需谨慎诊断,结合MR可能避免误诊。

要点

  • 68Ga-FAPI-04局灶性胰腺摄取可发生于假性囊肿、既往胰腺炎和IgG4相关疾病等良性病变。
  • 良性胰腺病灶的68Ga-FAPI-04 SUVmax范围3.1-9.1,对应18F-FDG摄取阴性。
  • 68Ga-FAPI-04 PET/MR结合MR可能有助于避免部分胰腺病变的误诊。

核心结论

  • 68Ga-FAPI-04局灶性胰腺摄取可发生于良性胰腺病变,应仔细评估以避免误诊。

研究设计与样本

  • 回顾性分析2020年5月22日至7月8日在本机构接受68Ga-FAPI-04 PET/MR的103例患者影像数据,其中7例胰腺局灶性摄取增高,4例同期行18F-FDG PET/CT。

主要发现

  • 7例患者胰腺出现局灶性68Ga-FAPI-04摄取增高,摄取可发生于胰腺任何部位,相应18F-FDG摄取阴性。
  • 多数病灶较小,CT或MR信号无明显变化,68Ga-FAPI-04 SUVmax范围3.1-9.1。
  • 所有胰腺病灶经病理确认或随访影像证实为非肿瘤性,包括胰腺假性囊肿、既往胰腺炎部位和IgG4相关疾病病灶。

临床怎么用

  • 阅读68Ga-FAPI-04 PET/MR时,对胰腺局灶性摄取应结合MR特征和临床背景鉴别良性病变,避免直接诊断为恶性肿瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 68Ga-Labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) has shown promise in tumour positron emission tomography (PET) imaging, including malignant pancreatic lesions. Here, we showed several non-malignant findings of focal 68Ga-FAPI-04 uptake in the pancreas which were occasionally found by PET/MR. The study aimed to investigate the reasons for the focal uptake and remind caution for the diagnosis. METHODS: We retrospectively analysed imaging data of 103 patients who underwent 68Ga-FAPI-04 PET/MR at our institute from May 22 to July 8, 2020. Seven patients had focally elevated uptake of 68Ga-FAPI-04 in the pancreas; four of these underwent simultaneous 18F-FDG PET/CT scans. The clinical data, PET/MR imaging features, pathological, and follow-up results were further collected and analysed. RESULTS: The cases showed that 68Ga-FAPI-04 accumulation can occur in any part of the pancreas, with corresponding negative 18F-FDG uptake. Most lesions were small with no significant changes in CT or MR signals. The SUVmax value of 68Ga-FAPI-04 had a wide range of 3.1-9.1. All the pancreatic lesions were proven to be non-neoplastic by pathology confirmation or follow-up imaging. Lesions with uptake were identified including pancreatic pseudocysts, sites of prior pancreatitis, and foci of IgG 4-related disease. CONCLUSION: Though 68Ga-FAPI-04 demonstrates great potential for oncological diagnosis, focal 68Ga-FAPI-04 uptake could occur in benign pancreatic lesions and should be carefully evaluated. Fortunately, combined with MR, 68Ga-FAPI-04 PET/MR may potentially avoid the misdiagnosis of some pancreatic lesions. CLINICAL TRIAL REGISTRATION: NCT04554719 and NCT04605939. Registered September 13, 2020 and October 25, 2020, respectively.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang X, Song W, Qin C, et al. Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas. Eur J Nucl Med Mol Imaging. 2021. PMID: 33452634. doi:10.1007/s00259-021-05194-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。